SynAct Pharma (SYNACT) Q2 2026 earnings summary

Executive summary

• Report covers Q2 and first half of 2026, focusing on R&D in inflammatory diseases, especially resomelagon for RA and viral infections.

• ADVANCE Phase 2b study topline data reported, supporting Phase 3 planning and business development.

• Positive momentum in partnering discussions and strategic financing secured to support ongoing and future studies.

Financial highlights

• Net sales were SEK 0 for both Q2 and H1 2026; company remains pre-revenue.

• Q2 operating expenses decreased 19% year-over-year to SEK 24,556 thousand.

• Q2 loss after tax was SEK 22,032 thousand, improved from SEK 27,522 thousand last year.

• Cash and cash equivalents at June 30, 2026, were SEK 14,228 thousand, down from SEK 68,890 thousand.

• Equity/assets ratio at 82% as of June 30, 2026.

Outlook and guidance

• Focus on advancing resomelagon to Phase 3 in RA and expanding into viral infection indications.

• Preparation for regulatory submissions to FDA and EMA in 2H 2026.

• Ongoing business development to secure commercial partnerships and additional funding.

• Cash runway expected to last into Q3 2027 following new financing facility.